← Back to Clinical Trials
Recruiting NCT04883502

NCT04883502 Study of the Role of the Induced Membrane in the Reconstruction of Bone Loss in the Limbs

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04883502
Status Recruiting
Phase
Sponsor Direction Centrale du Service de Santé des Armées
Condition Bone Loss
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2021-10-29
Primary Completion 2028-04

Trial Parameters

Condition Bone Loss
Sponsor Direction Centrale du Service de Santé des Armées
Study Type OBSERVATIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-10-29
Completion 2028-04
Interventions
Blood sample collectionOther biological sample collectionSurgical waste collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Masquelet's induced membrane technique is a two-stage reconstructive surgery for severe bone fractures commonly used by military orthopedists. The particularity of this technique relies on the synthesis of a biological membrane induced by the transient implantation of a surgical cement (= 1st stage surgery). The presence of the induced membrane in the reconstruction space defines a microenvironment or "biological chamber" favourable to osteogenesis, positively influencing the repair of the lesion after implantation of an autologous bone graft (= 2nd stage of surgery). In view of the excellent clinical results obtained with this procedure, the Masquelet technique has gradually become a reference treatment in the field of orthopedic and trauma surgery. However, orthopedic surgeons sometimes observe failures in bone consolidation. To our knowledge, the role played by induced membrane in these therapeutic failures has never been studied.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Patient with traumatic bone loss * Patient eligible for the induced membrane technique Exclusion Criteria: * Patients with post-tumor bone loss * Patients who are immunocompromised or under immunosuppressive treatment * Patients with chronic inflammatory disease (diabetes, inflammatory bowel disease) * Patients with collagenosis * Patient with a contraindication to sampling * Pregnant or breastfeeding women

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology